Business Context and Reporting Period
Company: Turn Therapeutics Inc. (TTRX)
Filing Type: Form 8-K (Current Report)
Date of Report: March 23, 2026
Event: Entry into a Material Definitive Agreement (Loan and Security Agreement) with Avenue Venture Opportunities Fund II, L.P.
Key Financial Metrics and Deal Structure
This filing details a new debt facility rather than historical financial performance. Key terms include:
- Total Loan Capacity: Up to $25.0 million in term loans.
- Tranche 1 (Immediate): $7.0 million funded within one business day of closing.
- Tranche 2 (Milestone-Based): Up to $8.0 million available between September 1, 2026, and March 31, 2027, contingent on clinical and financing milestones.
- Tranche 3 (Discretionary): Up to $10.0 million available between January 1, 2027, and June 30, 2028, subject to Tranche 2 funding, milestones, and mutual agreement.
- Interest Rate: The greater of (5.50% + Prime Rate) or 12.25% annually.
- Maturity Date: October 1, 2029.
- Collateral: Secured by a lien on all Company assets, including intellectual property.
- Equity Grant: Issuance of common stock valued at $1.2 million to the Lender at closing.
- Commitment Fee: $150,000 total ($50,000 previously paid).
Material Changes and Terms
The filing represents a significant change in the Company's capital structure through the addition of secured debt and equity issuance.
- Repayment Terms: Interest-only payments for 15 months from closing, with potential extensions of 9 months (upon Tranche 2 funding) and 6 months (upon Tranche 3 milestone). Principal repayable in equal monthly installments thereafter.
- Prepayment Penalties: 3.0% fee if prepaid within the first year; 2.0% in the second year; 1.0% thereafter.
- Final Payment: A 3.75% fee on the aggregate funded amount due at maturity or full prepayment.
- Conversion Option: Lender may convert up to $2.0 million of principal (increasing to $3.0 million upon Tranche 2 funding) into common stock at 80% of the closing price on the exercise date.
- Participation Right: Lender may participate in future equity financings up to $1.0 million on the same terms as other investors.
Guidance, Risks, and Contingencies
Management Commentary: The Company issued a press release on March 24, 2026, announcing the agreement. The filing includes standard forward-looking statements regarding clinical progress and financing efforts.
Risks and Contingencies:
- Milestone Dependency: Access to $18.0 million of the total facility (Tranches 2 and 3) is contingent on achieving specific clinical and financing milestones.
- Dilution Risk: The Conversion Option allows the lender to purchase equity at a 20% discount to market price, and the Participation Right allows the lender to maintain ownership percentage in future rounds.
- Covenants: The agreement limits additional indebtedness, liens, mergers, asset sales, and affiliate transactions.
- Events of Default: Include non-payment, covenant breaches, insolvency, and material adverse effects.
Investor Verification Checklist
- Verify the specific clinical and financing milestones required to unlock Tranche 2 ($8.0M) and Tranche 3 ($10.0M).
- Confirm the current cash balance and burn rate to assess runway with the initial $7.0M tranche.
- Review the exact number of shares issued for the $1.2 million Equity Grant and the resulting dilution impact.
- Monitor the Company's ability to meet the interest-only period requirements to avoid early principal repayment.
- Assess the impact of the 3.75% final payment fee on total cost of capital.